• Centrus Energy has in recent months secured a US$900 million High-Assay Low-Enriched Uranium contract from the U.S. Department of Energy and committed hundreds of millions of dollars to expand its Oak Ridge and Piketon enrichment plants, reinforcing its role in a reshaped Western nuclear fuel supply chain.
• An important takeaway is that Centrus now sits at the center of a multi‑billion‑dollar backlog through 2040, reflecting how policy shifts away from Russian uranium have turned its unique HALEU license and enrichment capacity into critical infrastructure for both conventional and advanced nuclear reactors.
• We’ll now examine how Centrus’ DOE HALEU award and large expansion plans might influence its existing investment narrative and risk profile.

Find 46 companies with promising cash flow potential yet trading below their fair value.

Centrus Energy Investment Narrative Recap

To own Centrus right now, you need to believe that its unique HALEU license, multibillion‑dollar backlog through 2040, and heavy capital build‑out will translate into durable nuclear‑fuel cash flows, despite recent earnings volatility and a sharply weaker share price. The latest news of an earnings miss and a pullback after Q4 2025 results does not fundamentally change the central near‑term catalyst, which is execution on its enrichment expansion, nor the main risk around capital intensity and project delivery.

The recent confirmation of a US$900 million HALEU award from the U.S. Department of Energy, paired with US$350–500 million of planned 2026 capex and the Oak Ridge and Piketon expansions, is the announcement that most directly ties into today’s debate. It reinforces the contract backlog behind the growth story but also magnifies execution, cost, and funding risks at a time when the stock has been highly volatile and is trading at an elevated earnings multiple.

Yet beneath that positive contract story, investors should be aware that concentrated government funding and a capital‑hungry build‑out could still...

Centrus Energy's narrative projects $640.9 million revenue and $70.3 million earnings by 2028.

Uncover how Centrus Energy's forecasts yield a $279.73 fair value, a 38% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were previously modeling revenue of about US$721 million and earnings near US$108 million by 2028, which assumes Centrus converts its exclusive HALEU position and DOE support into much faster growth than consensus expects; given this latest contract win and earnings wobble, you should recognize that views on contract reliance and execution risk can differ widely and may shift as new information comes through.

Explore 8 other fair value estimates on Centrus Energy - why the stock might be worth 48% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Centrus Energy research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Centrus Energy research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Centrus Energy's overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 27 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.